Hospital Dentistry Approach to a Patient with Mucormycosis treated with Amphotericin B: Case Report
Article Sidebar
Main Article Content
Abstract
This study addresses rhino-orbito-cerebral mucormycosis, a serious and opportunistic fungal infection, especially in immunosuppressed patients, such as those with type II diabetes mellitus. The study highlights the importance of a multidisciplinary approach in diagnosing and treating this condition, emphasizing collaboration between medical and dental specialties. Through a clinical case, it demonstrates how early and coordinated intervention can minimize the devastating consequences of the infection, underscoring amphotericin B, especially in its liposomal form, as the preferred treatment and the need for surgical debridement. The study reinforces the vigilance and early recognition of mucormycosis symptoms, particularly in patients with risk factors such as uncontrolled diabetes, illustrating the importance of integration between different medical fields in managing complex diseases.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Skiada A, Lass-Flörl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018 Apr;56(suppl 1):93-101. doi: 10.1093/mmy/myx101. PMID: 29538730; PMCID: PMC6251532.
Tavares RM, Leite CEA, Tavares RM, Oliveira PL, de Quental OB. Aspergilose e mucormicose–micoses sistêmicas de importância em COVID-19: Artigo de revisão. Pesq Soc Desenvolvimento. 2021;10(7):e59410717101.
Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol. 2023 Sep;21(13):1254919. doi: 10.3389/fcimb.2023.1254919. PMID: 37808914; PMCID: PMC10552646.
Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin North Am. 2021 Jun;35(2):435-452. doi: 10.1016/j.idc.2021.03.009. PMID: 34016285; PMCID: PMC10110349.
Yong JY, Chong KL, Gan WF, Zaidan NZ. Mucormycosis: A Case Series. Cureus. 2023 Jul;15(7):e41375. doi: 10.7759/cureus.41375. PMID: 37546065; PMCID: PMC10400303.
Motamedi M, Golmohammadi Z, Yazdanpanah S, Saneian SM, Shafiekhani M. Epidemiology, clinical features, therapeutic interventions and outcomes of mucormycosis in Shiraz: an 8-year retrospective case study with comparison between children and adults. Sci Rep. 2022 Oct;12(1):17174. doi: 10.1038/s41598-022-21611-8. PMID: 36229497; PMCID: PMC9561111.
Hernández JL, Buckley CJ. Mucormycosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Updated 2023 Jun 12. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544364/.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, Chen SC. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019 Jan;25(1):26-34. doi: 10.1016/j.cmi.2018.07.011. Epub 2018 Jul 21. PMID: 30036666.
Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018 Jan;56(1):29-43. doi: 10.1093/mmy/myx017. PMID: 28431008.
Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012 Feb;54(Suppl 1):S55-60. doi: 10.1093/cid/cir868. PMID: 22247446.
López-Muñoz A, Nicolás FE, García-Moreno D, Pérez-Oliva AB, Navarro-Mendoza MI, Hernández-Oñate MA, Herrera-Estrella A, Torres-Martínez S, Ruiz-Vázquez RM, Garre V, Mulero V. An Adult Zebrafish Model Reveals that Mucormycosis Induces Apoptosis of Infected Macrophages. Sci Rep. 2018 Aug;8(1):12802. doi: 10.1038/s41598-018-30754-6. PMID: 30143654; PMCID: PMC6109148.
Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Med. 2020 Sep;30(3):101007. doi: 10.1016/j.mycmed.2020.101007. Epub 2020 Jun 20. PMID: 32718789.
Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, Herbrecht R, Wolff M, Ribaud P, Lortholary O; French Mycosis Study Group. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015 Nov;70(11):3116-23. doi: 10.1093/jac/dkv236. Epub 2015 Aug 27. PMID: 26316385.
Mora-Martínez A, Murcia L, Rodríguez-Lozano FJ. Oral Manifestations of Mucormycosis: A Systematic Review. J Fungi (Basel). 2023 Sep;9(9):935. doi: 10.3390/jof9090935. PMID: 37755045; PMCID: PMC10533187.